HAVCR2 and lymphoma: In this study, we evaluated the use of intratumoral administration of a variety of combinations of immune-activating agents, including allogeneic GM-CSF-secreting cells, Poly(I:C), OX40 agonism and/or TIM-3 inhibition on A20 lymphoma control and long-term survival of mice [24,25,26].